Repligen Competitors

Amgen (NASDAQ:AMGN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Amgen and Repligen, as reported by MarketBeat.com.

Amgen presently has a consensus target price of $255.6190, suggesting a potential upside of 1.69%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Amgen.

Earnings & Valuation

This table compares Amgen and Repligen's revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Repligen. Amgen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Repligen's net margins, return on equity and return on assets.

Gilead Sciences (NASDAQ:GILD) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Gilead Sciences and Repligen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Earnings & Valuation

This table compares Gilead Sciences and Repligen's revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Repligen. Gilead Sciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Gilead Sciences and Repligen, as reported by MarketBeat.com.

Gilead Sciences presently has a consensus target price of $100.5909, suggesting a potential upside of 46.78%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 29.54%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Repligen.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Vertex Pharmaceuticals and Repligen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Repligen. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Vertex Pharmaceuticals and Repligen, as reported by MarketBeat.

Vertex Pharmaceuticals currently has a consensus target price of $293.4737, indicating a potential upside of 35.19%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Vertex Pharmaceuticals' higher possible upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Repligen.

Summary

Vertex Pharmaceuticals beats Repligen on 10 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Regeneron Pharmaceuticals and Repligen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Repligen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Regeneron Pharmaceuticals and Repligen, as reported by MarketBeat.

Regeneron Pharmaceuticals currently has a consensus target price of $656.3810, indicating a potential upside of 27.05%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Repligen on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Profitability

This table compares Biogen and Repligen's net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Repligen. Biogen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Biogen and Repligen, as reported by MarketBeat.

Biogen currently has a consensus target price of $305.5714, indicating a potential upside of 9.05%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Biogen.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Repligen. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Alexion Pharmaceuticals and Repligen, as reported by MarketBeat.

Alexion Pharmaceuticals currently has a consensus target price of $159.3158, indicating a potential downside of 8.17%. Repligen has a consensus target price of $222.75, indicating a potential upside of 29.54%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Repligen's net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Repligen on 9 of the 14 factors compared between the two stocks.